Yahoo Web Search

Search results

1. www.merck.com › news › merck-completes-acquisitionMerck Completes Acquisition of Acceleron Pharma Inc.

   www.merck.com › news › merck-completes-acquisition

   • Cached

   Nov 22, 2021 · Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder.

   • Merck to Acquire Acceleron Pharma Inc. - Merck.com

     Acceleron’s REBLOZYL (luspatercept-aamt) is the first and...

   • Merck Begins Tender Offer to Acquire Acceleron Pharma Inc.

     KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known...

2. www.merck.com › news › merck-to-acquire-acceleronMerck to Acquire Acceleron Pharma Inc. - Merck.com

   www.merck.com › news › merck-to-acquire-acceleron

   • Cached

   Sep 30, 2021 · Acceleron’s REBLOZYL (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders. REBLOZYL is being developed as part of a global collaboration with Bristol Myers Squibb.

3. Videos

   • 

     5:11

     youtube.com

     What to know about Merck's acquisition of Acceleron Pharma

     30 Sep 2021

     2.6K views

   • 

     5:10

     cnbc.com

     What to know about Merck's acquisition of Acceleron Pharma

     30 Sep 2021

   • 

     2:04

     cnbc.com

     Merck to acquire Acceleron Pharma in $11.5 billion deal

     29 Sep 2021

   View all

4. www.businesswire.com › news › homeMerck Completes Acquisition of Acceleron Pharma Inc.

   www.businesswire.com › news › home

   • Cached

   Nov 22, 2021 · Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary...

5. www.reuters.com › business › healthcareMerck to buy Acceleron for about $11.5 bln in rare disease ...

   www.reuters.com › business › healthcare

   Sep 30, 2021 · Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in...

6. www.merck.com › news › merck-begins-tender-offer-toMerck Begins Tender Offer to Acquire Acceleron Pharma Inc.

   www.merck.com › news › merck-begins-tender-offer-to

   • Cached

   Oct 12, 2021 · KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Acceleron Pharma Inc. (Nasdaq: XLRN).

7. www.ft.com › content › fcdce534-c6ae-4261-bac5Merck to buy Acceleron Pharma for $11.5bn - Financial Times

   www.ft.com › content › fcdce534-c6ae-4261-bac5

   • Cached

   Sep 30, 2021 · Merck has struck an $11.5bn deal to buy Acceleron Pharma to expand its growing pipeline of cardiovascular treatments, and said it is on the hunt for further acquisition opportunities.

8. People also ask

   Will Merck buy Acceleron Pharma?

   • REUTERS/Brendan McDermid Purchase Licensing Rights Sept 30 (Reuters) - Merck & Co (MRK.N) said on Thursday it would buy Acceleron Pharma Inc (XLRN.O) for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh revenue.

   Merck to buy Acceleron for about $11.5 bln in rare disease drug push

   www.reuters.com/business/healthcare-pharmaceuticals/merck-buy-acceleron-about-115-bln-rare-disease-drugs-push-2021-09-30/

   See all results for this question

   Does Acceleron Pharma Inc (Acceleron) offer to buy or sell shares?

   • This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of Acceleron Pharma Inc. (Acceleron) or any other securities, nor is it a substitute for the tender offer materials described herein.

   Merck to Acquire Acceleron Pharma Inc. - Merck.com

   www.merck.com/news/merck-to-acquire-acceleron-pharma-inc/

   See all results for this question

   How much does Acceleron cost?

   • The US life sciences group said on Thursday it would acquire US-listed Acceleron for $180 per share in cash in a deal that is expected to close in the fourth quarter. It is the latest in a series of acquisitions of emerging companies by large pharma groups aiming to secure access to blockbuster drugs to boost future revenues.

   Merck to buy Acceleron Pharma for $11.5bn - Financial Times

   www.ft.com/content/fcdce534-c6ae-4261-bac5-660286c82b25

   See all results for this question

   Why did Merck buy Acceleron & Keytruda?

   • The deal gives Merck access to Acceleron's rare disease drug candidate, sotatercept, which the company expects could bring in billions of dollars in sales, and comes as Keytruda moves toward the loss of market exclusivity in 2028. The lung cancer treatment accounted for 36.7%, or $4.18 billion, of Merck's total sales in the second quarter.

   Merck to buy Acceleron for about $11.5 bln in rare disease drug push

   www.reuters.com/business/healthcare-pharmaceuticals/merck-buy-acceleron-about-115-bln-rare-disease-drugs-push-2021-09-30/

   See all results for this question

9. www.nasdaq.com › press-release › merck-to-acquireMerck to Acquire Acceleron Pharma Inc. | Nasdaq

   www.nasdaq.com › press-release › merck-to-acquire

   • Cached

   Sep 30, 2021 · Acceleron’s REBLOZYL (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, Canada and Australia for the treatment of anemia in certain...